⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573873 | 0.84 | CES1 (0.48) | — | |
| SCHEMBL11580294 | 0.82 | CES2 (0.50) | — | |
| SCHEMBL27847497 | 0.80 | CES2 (0.52) | — | |
| SCHEMBL28090532 | 0.80 | CES2 (0.52) | — | |
| SCHEMBL5731663 | 0.77 | — | — | |
| SCHEMBL7814636 | 0.74 | — | — | |
| SCHEMBL27493253 | 0.74 | — | — | |
| SCHEMBL8706144 | 0.74 | — | — | |
| SCHEMBL8706148 | 0.74 | — | — | |
| Hexanoate SCHEMBL27681443 | 0.74 | GPR84 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037011-A2 | NOVEL USES | TEITUR TROPHICS APS (DK) | 2025-02-20 | — | — | WO | disclosed |
| EP-4475890-A1 | NOVEL PEPTIDES | Teitur Trophics ApS (DK) | 2024-12-18 | — | — | EP | disclosed |
| CN-118804766-A | Novel peptides | 泰图尔特罗菲克斯有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023152229-A1 | NOVEL PEPTIDES | TEITUR TROPHICS APS (DK) | 2023-08-17 | — | — | WO | disclosed |
| US-20210024604-A1 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2021-01-28 | — | — | US | disclosed |
| US-20200172593-A1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2020-06-04 | — | — | US | disclosed |
| US-20180371045-A1 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2018-12-27 | — | — | US | disclosed |
| EP-2448962-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2016-10-19 | — | — | EP | disclosed |
| US-20160229902-A1 | Novel Insulin Derivatives | NOVO NORDISK AS (DK) | 2016-08-11 | — | — | US | disclosed |
| US-20120184487-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-07-19 | — | — | US | disclosed |
| EP-2448962-A1 | INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011000823-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-01-06 | — | — | WO | disclosed |
| EP-1736465-A1 | ANILINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1058680-A1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999043657-A1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-02 | — | — | WO | disclosed |